MRKMerck Sharp & Dohme LLCSigning up patients
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Endometrial Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,123 (planned)
- Started
- May 22, 2025
- Main results expected
- May 24, 2032
- Fully finished
- May 24, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maintenance Treatment: Progression-Free Survival (PFS)
Measured over: Up to approximately 44 months
Maintenance Treatment: Overall Survival (OS)
Measured over: Up to approximately 54 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06952504 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC